SAN DIEGO, June 16, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA) today announced that it is further strengthening its Executive Team with the appointment of Bob Goodenow, Ph.D., as Chief Business Officer.
Dr. Goodenow has more than 25 years of senior management experience in the biotech and pharmaceutical industries, spanning research and development, marketing and business development.
"It is a great pleasure to welcome Dr. Bob Goodenow to the HUYA Executive Team, where he joins Alain Rolland, Pharm.D., Ph.D., Executive Vice President and Chief Scientific Officer, Mr. John Sharp, CPA, Chief Financial Officer, and Mr. Clem Gingras, Chief Technology Officer & Chief Operating Officer, Asia," said Mireille Gillings Ph.D., CEO of HUYA. "Bob's extensive global experience in the business and commercial aspects of oncology will be particularly valuable for HUYA going forward."
Most recently, Dr. Goodenow was Chief Business Officer at Syndax Pharmaceuticals (Waltham, Massachusetts), a late stage, privately held oncology company. Previously, he was Vice President, Corporate Development, at Inovio Biomedical and held numerous senior level positions in Corporate Marketing, Business Development, and Research and Development for RPR, Aventis and Baxter Healthcare.
Dr. Goodenow holds an A.B. in Biochemistry from the University of California, Berkeley, and a Ph.D. in Biophysics from Stanford University Medical School. He was a CALTECH American Cancer Society Lievre Fellow in the Division of Biology.
About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan and eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. In April 2015, HUYA was named the winner of a Stevie® Award in the Health Products & Services and Pharmaceuticals category in the Asia-Pacific Stevie Awards. www.huyabio.com
Jill Dawson, Ph.D. Corporate Communications
HUYA Bioscience International
SOURCE HUYA Bioscience International